Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Other financing activities (2023 - 2025)

Historic Other financing activities for BioXcel Therapeutics (BTAI) over the last 3 years, with Q3 2025 value amounting to $686000.0.

  • BioXcel Therapeutics' Other financing activities rose 480000.0% to $686000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 35531.34%. This contributed to the annual value of $474000.0 for FY2024, which is 4155.36% down from last year.
  • Per BioXcel Therapeutics' latest filing, its Other financing activities stood at $686000.0 for Q3 2025, which was up 480000.0% from $3000.0 recorded in Q2 2025.
  • BioXcel Therapeutics' Other financing activities' 5-year high stood at $803000.0 during Q1 2025, with a 5-year trough of $3000.0 in Q2 2025.
  • Over the past 3 years, BioXcel Therapeutics' median Other financing activities value was $164000.0 (recorded in 2024), while the average stood at $308555.6.
  • Within the past 5 years, the most significant YoY rise in BioXcel Therapeutics' Other financing activities was 480000.0% (2025), while the steepest drop was 9817.07% (2025).
  • Quarter analysis of 3 years shows BioXcel Therapeutics' Other financing activities stood at $72000.0 in 2023, then skyrocketed by 148.61% to $179000.0 in 2024, then surged by 283.24% to $686000.0 in 2025.
  • Its Other financing activities stands at $686000.0 for Q3 2025, versus $3000.0 for Q2 2025 and $803000.0 for Q1 2025.